Quick Read – AbbVie’s post-Humira transition succeeded with 12% Q1 revenue growth, while JNJ’s 64-year dividend streak and AAA credit make it the portfolio’s quality anchor. – Coca-Cola delivered 12% Q1 revenue growth and 10% organic growth, raised full-year EPS guidance, and…
ys its next $0.53 quarterly dividend on July 1. – Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Johnson & Johnson didn’t make the cut. Grab the names FREE today
Dividend investors entering July 2026 have a rare setup: Three of the market’s most reliable income stocks all delivered beat-and-raise first-quarter reports, all hiked their payouts in the past 12 months and all three are riding meaningful momentum into the back half of the year. The thesis is simple. When defensive cash-flow machines start outperforming, income compounding does the heavy lifting while you wait.
Here are three dividend names worth watching closely this month, each chosen for a different reason so they complement rather than duplicate each other in a portfolio. AbbVie (ABBV) AbbVie (NYSE:ABBV) is the growth-flavored pick of the three. The post-Humira transition is no longer theoretical: Skyrizi posted $4.48 billion in Q1 sales (+31%) and Rinvoq added $2.12 billion (+23%), more than offsetting a 39% Humira decline.